Sir,
A review of the literature showed no published cases using a combination of intravitreal triamcinolone acetonide (IVTA) and antivascular endothelial growth factor agents for choroidal neovascularization (CNV) with associated retinal angiomatous proliferation (RAP).1, 2, 3, 4, 5 We present a case of RAP with a pigment epithelial detachment (PED) refractory to multiple treatment modalities, but which responded to the combination of intravitreal triamcinolone (Kenalog, Bristol-Myers-Squibb, Peapack, NJ, USA) and intravitreal bevacizumab (Avastin; Genentech, San Francisco, CA, USA).
An 80-year-old woman with bilateral AMD was referred for treatment of CNV. Her vision was 20/150 right eye (OD) and counting fingers at 5 feet left eye (OS). Clinical examination showed bilateral fibrovascular PEDs with overlying small coin-shaped geographic atrophy both eyes (OU). There was intraretinal haemorrhage and lipid associated with the PEDs. Fluorescein angiography and indocyanine green angiography showed leakage from minimally classic CNV with RAP lesions OU (Figure 1a and b). Optical coherence tomography (OCT) showed a PED, cystoid macular oedema (CME), and subretinal fluid OU (Figure 2).
Over the previous 9 months before referral, the patient had been treated with three sessions of verteporfin photodynamic therapy (PDT), the last combined with intravitreal triamcinolone. Over the next 20 months, she underwent multiple treatments, including two PDTs with IVTA, pegaptanib (Macugen, Eyetech, New York NY, USA) OD, four bevacizumab OD, two bevacizumab OS, one ranibizumab (Lucentis; Genentech, San Francisco, CA, USA) OD and three ranibizumab OS. After the third bevacizumab OD, the OCT showed a flat PED, vision improved to 20/70, and the PED remained flat without further treatments for 9 months. However, the CME in the left eye continued to worsen on OCT despite the last three ranibizumab injections (Figure 3a). After a discussion with the patient on combination therapies, intravitreal triamcinolone 2 mg (0.05 ml) and intravitreal bevacizumab 1.25 mg (0.05 ml) were given. This dose allowed us to give a single 0.1-ml injection without the need for a paracentesis. One month later, the CME had resolved and the PED was flat (Figure 3b). The vision remained at counting fingers due to the areas of geographic atrophy. This effect was maintained the last follow-up 5 months later with no adverse treatment effects.
Intravitreal bevacizumab and triamcinolone are used off-label as treatment options for CNV. This case illustrates that combination therapy with intravitreal triamcinolone and bevacizumab may be considered as an option for treatment of CNV.
References
Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439–444.
Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 2007; 27: 451–457.
Augustin AJ, Schmidt-Erfurth U . Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638–645.
Nicolo M, Ghiglione D, Lai S, Calabria G . Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1336–1338.
Costagliola C, Romano MR, dell'Omo R, Cipollone U, Polisena P . Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol 2007; 144 (3): 449–451.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bakri, S., Ekdawi, N. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation. Eye 22, 978–980 (2008). https://doi.org/10.1038/sj.eye.6703041
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6703041